The diamond burr has been used in the management of corneal lesions in humans since 1983. Recently, it has been successfully used in the treatment of SCCEDs in dogs; however, little has been documented as to its mechanism of action.

Methods Five adult female research dogs euthanized for reasons unrelated to the study were included, providing AZD6738 10 normal eyes. An excimer laser spatula was used for epithelial removal after delineation with an 8 mm punch biopsy trephine. Diamond burr debridement was performed for 30 and 45 s in five eyes each (groups 1 and 2 respectively). The procedure was performed on the ventral half of the experimental defect as well as ventral

normal cornea, immediately after euthanasia, and prior to enucleation. Samples were processed routinely for histologic evaluation and stained with periodic acid-Schiff.

Results No stromal defects could be identified under light microscopy. In experimental corneal wounds, multi-focal areas remained covered by the epithelial basement membrane (BM) after diamond burr treatment in both groups (group 1 = 48% +/- 16SD, group 2 = 26% +/- 12SD). Removal of BM on group 2 was significantly higher than group 1 (P < 0.05).

Conclusions The diamond burr allows a safe method of debridement and does not create defects beyond the epithelial BM in corneal wounds in normal dogs. Evaluation of the diamond burr debridement in cases of SCCEDs

is warranted.”
“Two new phenylpropanoids, methyl 3-(2,4-dihydroxy-5-methoxyphenyl)propionate GSK1210151A in vivo (1) and butyl 3-(2,4-dihydroxy-5-methoxyphenyl)propionate (2), and one unusual propanoate, 5-hydroxyhexyl 2-hydroxypropanoate (3), were isolated from the fruits of Morinda citrifolia. Their structures were

established using MS and NMR methods.”
“This study was undertaken to evaluate outcomes for single (SLT) vs. bilateral lung transplantation (BLT) in patients with interstitial lung disease (ILD). One hundred and eleven patients with ILD who underwent lung transplantation between January 1993 and March 2009 were evaluated. Recipients with BLT were younger (43 +/- 12 vs. 57 +/- 7 years), and significantly more patients Tubastatin A in vitro with non-idiopathic pulmonary fibrosis (IPF) received BLT (50%) vs. patients with IPF (18%). BLT recipients had a significantly longer mean waitlist time (240 vs. 125 days), significantly higher systolic (51 +/- 18 vs. 40 +/- 11 mmHg) pulmonary artery pressures, were placed on cardiopulmonary bypass more frequently (67 vs. 31%), had a higher incidence of primary graft dysfunction (63 vs. 17%), more frequently were given prolonged peri-operative inhaled nitric oxide and more frequently required prolonged post-operative mechanical ventilatory support (6.0 vs. 1.7 days). Additionally, BLT recipients had a significantly longer intensive care unit (8 vs. 4 days) and hospital (24 vs. 15 days) length of stay. We did not detect a difference in survival (Kaplan-Meier) for SLT vs. BLT.